1. Market Research
  2. > Biotechnology Market Trends
  3. > Vivia Biotech, S.L. - Product Pipeline Review - 2013

Vivia Biotech, S.L. - Product Pipeline Review - 2013

  • December 2013
  • -
  • Global Markets Direct
  • -
  • 19 pages

Vivia Biotech, S.L. - Product Pipeline Review - 2013

Summary

Global Market Direct’s pharmaceuticals report, “Vivia Biotech, S.L. - Product Pipeline Review - 2013” provides data on the Vivia Biotech, S.L.’s research and development focus. The report includes information on current developmental pipeline, complete with latest updates, and features on discontinued and dormant projects.

This report is built using data and information sourced from Global Markets Direct’s proprietary databases, Vivia Biotech, S.L.’s corporate website, SEC filings, investor presentations and featured press releases, both from Vivia Biotech, S.L. and industry-specific third party sources, put together by Global Markets Direct’s team.

Scope

- Vivia Biotech, S.L. - Brief Vivia Biotech, S.L. overview including business description, key information and facts, and its locations and subsidiaries.
- Review of current pipeline of Vivia Biotech, S.L. human therapeutic division.
- Overview of pipeline therapeutics across various therapy areas.
- Coverage of current pipeline molecules in various stages of drug development, including the combination treatment modalities, across the globe.
- Product profiles for late stage and clinical stage products of Vivia Biotech, S.L. with complete description of the product’s developmental history, mechanism of action, therapeutic class, target and major milestones.
- Recent updates of the Vivia Biotech, S.L.’s pipeline in the last quarter.
- Key discontinued and dormant projects.
- Latest news and deals relating to the products.

Reasons to buy

- Evaluate Vivia Biotech, S.L.’s strategic position with total access to detailed information on its product pipeline.
- Assess the growth potential of Vivia Biotech, S.L. in its therapy areas of focus.
- Identify new drug targets and therapeutic classes in the Vivia Biotech, S.L.’s R&D portfolio and develop key strategic initiatives to reinforce pipeline in those areas.
- Exploit in-licensing opportunities by identifying windows of opportunity to fill portfolio gaps.
- Exploit collaboration and partnership opportunities with Vivia Biotech, S.L..
- Avoid Intellectual Property Rights related issues.
- Explore the dormant and discontinued projects of Vivia Biotech, S.L. and identify potential opportunities in those areas.

Table Of Contents

Vivia Biotech, S.L. - Product Pipeline Review - 2013
Table of Contents

Table of Contents 2
List of Tables 3
List of Figures 3
Vivia Biotech, S.L. Snapshot 4
Vivia Biotech, S.L. Overview 4
Key Information 4
Key Facts 4
Vivia Biotech, S.L. - Research and Development Overview 5
Key Therapeutic Areas 5
Vivia Biotech, S.L. - Pipeline Review 7
Pipeline Products by Stage of Development 7
Pipeline Products - Monotherapy 8
Vivia Biotech, S.L. - Early Stage Pipeline Products 9
Preclinical Products/Combination Treatment Modalities 9
Vivia Biotech, S.L. - Drug Profiles 10
Vivia-007 10
Product Description 10
Mechanism of Action 10
RandD Progress 10
Vivia-008 11
Product Description 11
Mechanism of Action 11
RandD Progress 11
Vivia-009 12
Product Description 12
Mechanism of Action 12
RandD Progress 12
Vivia-1615 13
Product Description 13
Mechanism of Action 13
RandD Progress 13
Vivia-577 14
Product Description 14
Mechanism of Action 14
RandD Progress 14
Vivia Biotech, S.L. - Pipeline Analysis 15
Vivia Biotech, S.L. - Pipeline Products by Therapeutic Class 15
Vivia Biotech, S.L. - Pipeline Products by Route of Administration 16
Vivia Biotech, S.L. - Locations And Subsidiaries 17
Head Office 17
Other Locations and Subsidiaries 17
Appendix 18
Methodology 18
Coverage 18
Secondary Research 18
Primary Research 18
Expert Panel Validation 18
Contact Us 19
Disclaimer 19



List of Tables

Vivia Biotech, S.L., Key Information 4
Vivia Biotech, S.L., Key Facts 4
Vivia Biotech, S.L. - Pipeline by Indication, 2013 6
Vivia Biotech, S.L. - Pipeline by Stage of Development, 2013 7
Vivia Biotech, S.L. - Monotherapy Products in Pipeline, 2013 8
Vivia Biotech, S.L. - Preclinical, 2013 9
Vivia Biotech, S.L. - Pipeline by Therapeutic Class, 2013 15
Vivia Biotech, S.L. - Pipeline by Route of Administration, 2013 16
Vivia Biotech, S.L., Other Locations 17



List of Figures

Vivia Biotech, S.L. - Pipeline by Top 10 Indication, 2013 6



Companies Mentioned

View This Report »

Get Industry Insights. Simply.

  • Latest reports & slideshows with insights from top research analysts
  • 24 Million searchable statistics with tables, figures & datasets
  • More than 10,000 trusted sources
24/7 Customer Support

Talk to Ahmad

+1 718 618 4302

Purchase Reports From Reputable Market Research Publishers
Glycoprotein 41 (gp41) - Pipeline Review, H2 2016

Glycoprotein 41 (gp41) - Pipeline Review, H2 2016

  • $ 3500
  • Company report
  • October 2016
  • by Global Markets Direct

Glycoprotein 41 (gp41) - Pipeline Review, H2 2016 Summary Global Markets Direct’s, ‘Glycoprotein 41 (gp41) - Pipeline Review, H2 2016’, provides in depth analysis on Glycoprotein 41 (gp41) targeted ...

Cellular Tumor Antigen p53 (Tumor Suppressor p53 or Phosphoprotein p53 or Antigen NY CO 13 or TP53) - Pipeline Review, H2 2016

Cellular Tumor Antigen p53 (Tumor Suppressor p53 or Phosphoprotein p53 or Antigen NY CO 13 or TP53) - Pipeline Review, H2 2016

  • $ 3500
  • Company report
  • September 2016
  • by Global Markets Direct

Cellular Tumor Antigen p53 (Tumor Suppressor p53 or Phosphoprotein p53 or Antigen NY CO 13 or TP53) - Pipeline Review, H2 2016 Summary Global Markets Direct’s, ‘Cellular Tumor Antigen p53 (Tumor Suppresso ...

Telomerase Reverse Transcriptase (HEST2 or Telomerase Catalytic Subunit or Telomerase Associated Protein 2 or TERT or EC 2.7.7.49) - Pipeline Review, H2 2016

Telomerase Reverse Transcriptase (HEST2 or Telomerase Catalytic Subunit or Telomerase Associated Protein 2 or TERT or EC 2.7.7.49) - Pipeline Review, H2 2016

  • $ 3500
  • Company report
  • October 2016
  • by Global Markets Direct

Telomerase Reverse Transcriptase (HEST2 or Telomerase Catalytic Subunit or Telomerase Associated Protein 2 or TERT or EC 2.7.7.49) - Pipeline Review, H2 2016 Summary Global Markets Direct’s, ‘Telomerase ...

Tetanus - Pipeline Review, H2 2016

September 2016 $ 2000

ref:plp2013

Reportlinker.com © Copyright 2016. All rights reserved.

ReportLinker simplifies how Analysts and Decision Makers get industry data for their business.